Supernus issued third U.S. patent for Oxtellar XR Supernus Pharmaceuticals announced the issuance of a third patent by the United States Patent and Trademark Office covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent was issued by the USPTO on December 31, 2013. It provides protection for the product with expiration that is no earlier than 2027.
News For SUPN From The Last 14 Days
Check below for free stories on SUPN the last two weeks.
Supernus to explore 'broad range of strategic opportunities' Supernus Pharmaceuticals is providing the following business update in light of recent investor filings with the SEC: "The company will explore a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion partnerships which are synergistic with our neurology sales force call point, potential co-development partnerships on our pipeline products, and growth opportunities through value-creating and transformative merger and acquisition transactions."